Brazil Medical Devices Market Report 2026: ANVISA Regulation, SUS Procurement, and Commercial Strategy Intelligence

The Brazilian medical devices market is estimated at USD 11–13 billion in 2026, making it the largest medical device market in Latin America. Brazil has the world's seventh-largest installed base of medical imaging equipment and a significant domestic manufacturing capability in segments including wound care, dental equipment, disposables, and hospital furniture. The market is split between SUS (public hospital procurement through state and municipal health secretariats, approximately 45%) and the private supplementary sector (hospital groups like Rede D'Or, UnitedHealth/Amil, and premium hospitals Einstein, Sírio-Libanês, accounting for 55%).

ANVISA (Agência Nacional de Vigilância Sanitária) regulates medical devices (Equipamentos e Materiais Médico-Hospitalares) in Brazil through a risk-based classification system. Devices are classified as Class I (lowest risk), Class II, Class III, and Class IV (highest risk). ANVISA registration is mandatory for all devices sold in Brazil — Class I requires only notification, while Class II–IV require full registration with technical dossier review. Registration timelines range from 3–12 months for Class I–II and up to 18–24 months for Class III–IV. ANVISA also oversees the Registro de Empresa de Serviço de Saúde (company registration) and Autorização de Funcionamento (AFE) for importers and distributors. Post-market surveillance includes mandatory adverse event reporting (Tecnovigilância) to ANVISA.

SUS (Sistema Único de Saúde) public hospital procurement follows Lei n° 8.666/93 and the newer Lei de Licitações (Lei n° 14.133/2021), requiring competitive public tender (licitação) processes for device purchases. Pregão eletrônico (electronic reverse auction) is the most common procurement modality. Federal hospitals (Empresa Brasileira de Serviços Hospitalares, EBSERH network of 40+ university hospitals) and state and municipal health secretariats each manage independent procurement. The PROQUALIS program and OPAS/PAHO frameworks provide guidance on quality standards for SUS device procurement. CONASS (National Council of State Health Secretariats) and CONASEMS coordinate procurement across the federated system. Import taxes (II, IPI, PIS, COFINS) can add 25–60% to device costs for imported products, creating a competitive advantage for locally manufactured devices.

The fastest-growing Brazilian medical device segments are: continuous glucose monitoring (CGM reimbursement through ANS mandates and SUS pilot programs; rapid prescription growth); diagnostics and molecular testing (post-COVID investment in laboratory and point-of-care diagnostic infrastructure); robotic surgery (Rede D'Or, Hospital Albert Einstein, and Hospital Sírio-Libanês expanding robotic surgical programs); oncology devices (infusion pumps, radiotherapy equipment, linear accelerators — driven by SUS cancer network and premium private oncology centres); and minimally invasive cardiovascular devices (TAVR, LAAO — in premium private hospitals at international price points). Dental and implantology devices remain a major domestic manufacturing segment.

Key challenges in the Brazil medical device market include: (1) ANVISA registration complexity and timeline — Class III/IV dossiers require complete technical documentation in Portuguese and can take 18–24 months; (2) Import tax burden — II + IPI + PIS + COFINS taxes can add 40–60% to device costs for fully imported products, disadvantaging international manufacturers versus local assembly; (3) SUS procurement delays — public tender processes can extend purchase cycles to 12–18 months from contract award to delivery; (4) Currency volatility — BRL/USD exchange rate fluctuations significantly impact pricing competitiveness; (5) Two-speed market — premium private hospitals (premium-priced, fast adoption) versus SUS public hospitals (price-sensitive, slow procurement) require fundamentally different commercial strategies.

BioNixus delivers medical device market research in Brazil: regulator-aware access intelligence, hospital consumption analogues, physician and payer qualitative programmes, and launch evidence under EphMRA and BHBIA governance with GDPR-aligned fieldwork for multinational sponsors. Teams receive decision-ready outputs validated against national policy and institution-level adoption—not desk extrapolation from unrelated regions.

BioNixus supports Brazil-based medical device companies expanding into GCC and MENA markets with SFDA and MOHAP regulatory intelligence, NUPCO and hospital procurement tracking in Saudi Arabia, UAE insurer and formulary research, physician panels across GCC countries, and comparative Brazil versus GCC market intelligence. GCC expansion is a distinct service line with its own tender and access calendars—see our GCC pharmaceutical market report for regional context. Launch assumptions should be validated market by market rather than from a single Gulf average.